Adverse Events Related to Tirzepatide.

Rahul Mishra Rishi Raj Ghada Elshimy Isain Zapata Lakshmi Kannan Priyanka Majety Dinesh Edem Riccardo Correa

Published in: Journal of the Endocrine Society (2023)

Tirzepatide is associated with a dose-dependent increase in incidence of GI AEs and AEs leading to drug discontinuation. Severe hypoglycemia, fatal AEs, acute pancreatitis, cholelithiasis, and cholecystitis are rare with this medication.

Keyphrases

type diabetes
adverse drug
drug induced
risk factors
healthcare
early onset
emergency department
glycemic control
metabolic syndrome
skeletal muscle